Abstract Objective Plasma phosphorylated‐tau‐181 (p‐tau181) reliably detects clinical
Alzheimer's disease (AD) as well as asymptomatic amyloid‐β (Aβ) pathology, but is …

Blood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations
with Alzheimer's disease (AD) neuropathologic change and clinical stage. Certain plasma p …

INTRODUCTION Detection of Alzheimer's disease (AD) pathophysiology among individuals
with mild cognitive changes and those experiencing subjective cognitive decline (SCD) …

Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based
biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p …

Introduction We examined and compared plasma phospho-tau181 (pTau181) and total
tau:(1) across the Alzheimer's disease (AD) clinical spectrum;(2) in relation to brain amyloid …

Background Blood-based biomarkers of Alzheimer's disease (AD) have become
increasingly important as scalable tools for diagnosis and determining clinical trial eligibility …

Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …

Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD),
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …

INTRODUCTION Plasma biomarkers are promising tools for Alzheimer's disease (AD)
diagnosis, but comparisons with more established biomarkers are needed. METHODS We …

Abstract Plasma phosphorylated-tau181 (p-tau181) showed the potential for Alzheimer's
diagnosis and prognosis, but its role in detecting cerebral pathologies is unclear. We aimed …